This site is for US Residents only

  • Carcinoid Syndrome


Only Somatuline Depot is FDA-approved with a dual indication for carcinoid syndrome and PFS1

In ELECT, Somatuline Depot reduced the number of days a rescue SSA was needed by 15% (absolute reduction)1,2

Somatuline® Depot reduced the need for rescue medication in patients with carcinoid syndrome vs placebo

A measurable treatment difference

  • With Somatuline Depot, patients experienced approximately 15% fewer days on rescue medication compared with placebo1
  • ~4.4 fewer days of rescue therapy per month; or potentially ~53 fewer days per year†2

Assuming the treatment difference in the 16 week intention-to-treat population could be maintained in the longer term.2

  • 31% relative reduction in patients’ need to use rescue medication1

Secondary endpoints: Average daily frequencies1

  • The average daily frequencies of diarrhea and flushing events in patients treated with Somatuline Depot (and rescue medication) were numerically lower relative to patients treated with placebo (and rescue medication) but were not statistically significantly different via hierarchical testing.

Adverse reactions reported in the ELECT study1

Adverse events occurring by Week 16 in ELECT in 5% of Somatuline Depot-treated patients and occurring at least 5% more than in placebo-treated patients were headache (12% vs 5%), dizziness (7% vs 0%), and muscle spasm (5% vs 0%).


Please also see ELECT trial study design and Patient Information below.

Please also see ELECT trial study design and Patient Information below.


ELECT:* A phase 3, 16-week, randomized, placebo-controlled, double-blind, pivotal trial2

Study design and patient information image

Patients were excluded if they had:2

  • History of carcinoid syndrome refractory to treatment with conventional doses of SSA
  • Treatment with interferon, chemotherapy, and/or peptide receptor radionuclide therapy, and/or tumor debulking <3 months before study entry
  • History of hepatic arterial embolization, hepatic arterial chemoembolization, and/or selective internal radiation therapy <6 months before study entry

If already being treated for GEP-NETs, there is no need to administer an additional dose for the treatment of carcinoid syndrome.


*ELECT=Evaluating Lanreotide Efficacy and safety as a Carcinoid-syndrome Treatment.2

Administered every 28 days by deep subcutaneous injection, with access to short-acting octreotide as rescue medication.2

Analysis of variance and ANCOVA models were applied using Statistical Analysis System (SAS®) version 8 or higher.2

GEP-NET=gastroenteropancreatic neuroendocrine tumor; LS=least squares; SSA=somatostatin analog.


  • Somatuline Depot (lanreotide) Injection [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; February 2023.
  • Vinik AI, Wolin EM, Liyanage N, et al.; on behalf of the ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068-1080.



  • SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.

Warnings and Precautions

  • Cholelithiasis and Gallbladder Sludge
    • SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation.
    • Periodic monitoring may be needed.
    • If complications of cholelithiasis are suspected, discontinue SOMATULINE DEPOT and treat appropriately.
  • Hypoglycemia or Hyperglycemia
    • Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.
    • Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
  • Cardiovascular Abnormalities
    • SOMATULINE DEPOT may decrease heart rate.
    • In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia.
    • In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.

Most Common Adverse Reactions

  • GEP-NETs: Adverse reactions in >10% of patients who received SOMATULINE DEPOT were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%).
  • Carcinoid Syndrome: Adverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. Adverse reactions in ≥5% of patients who received SOMATULINE DEPOT and at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%).

Drug Interactions

  • SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed); increase the absorption of bromocriptine; and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).

Special Populations

  • Lactation: Advise women not to breastfeed during treatment and for 6 months after the last dose.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or


  • SOMATULINE® DEPOT (lanreotide) is a somatostatin analog indicated for: the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and
  • the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.